SAGHMOS THERAPEUTICS
SAGHMOS THERAPEUTICS
Industry:
Biotechnology Medical Medical Device Pharmaceutical
Address:
Greenwich, Connecticut, United States
Country:
United States
Status:
Active
Contact:
914-522-3885
Similar Organizations
Omnitura Therapeutics
Omnitura Therapeutics is a biopharmaceutical company .
More informations about "Saghmos Therapeutics"
Saghmos Therapeutics 2025 Company Profile: Valuation, Funding ...
Saghmos Therapeutics General Information Description. Operator of a privately held biopharmaceutical company intended for life-threatening cardiovascular and renal diseases …See details»
Saghmos Therapeutics - LinkedIn
Saghmos Therapeutics is a privately held biopharmaceuticals company with a Phase 3-ready cardiorenal metabolic modulator ST-62516 (trimetazidine). Saghmos’ IND for ST-62516 was cleared by the ...See details»
Saghmos Therapeutics - VentureRadar
Saghmos Therapeutics is a privately held biopharmaceutical company whose mission is to prevent and treat kidney injury due to contrast dyes. Saghmos’ lead program, ST-62516 is …See details»
Saghmos Therapeutics - BioCT
15 East Putnam Avenue, #430 Greenwich, CT 06830. Phone: 914-522-3885 Fax: 914-206-3548. Email: [email protected] General Information: Saghmos Therapeutics is a privately held …See details»
Saghmos Therapeutics, Inc. - BIO CEO & Investor Conference | BIO
Feb 6, 2023 Saghmos Therapeutics is a privately held biopharmaceutical company whose mission is to develop innovative therapies for life-threatening cardiovascular and renal …See details»
Saghmos Therapeutics Announces Collaboration with Duke Clinical ...
Apr 17, 2024 DCRI is the world’s largest academic clinical research organization and a pioneer in cardiovascular clinical research, combining clinical and academic leadership with …See details»
Saghmos Therapeutics - Contacts, Employees, Board Members, …
Organization. Saghmos Therapeutics . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. About. Saghmos …See details»
Saghmos Therapeutics, Inc. Company Profile | Greenwich, CT ...
Find company research, competitor information, contact details & financial data for Saghmos Therapeutics, Inc. of Greenwich, CT. Get the latest business insights from Dun & Bradstreet.See details»
Saghmos Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Saghmos Therapeutics is collaborating with the Duke Clinical Research Institute to optimize and operationalize the Phase 3 study for ST-62516. Forward looking statements This press …See details»
Anna Kazanchyan, MD - BIO CEO & Investor Conference | BIO
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... Anna Kazanchyan, M.D. is …See details»
Saghmos Therapeutics Announces Receipt of Notice of Allowance …
GREENWICH, Conn., March 12, 2024--Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced that it has received a Notice of Allowance from the …See details»
Saghmos Therapeutics-Saghmos Therapeutics, Inc.-企业详情 …
Dec 31, 2015 Saghmos Therapeutics is a privately held biopharmaceutical company whose mission is to prevent and treat kidney injury due to contrast dyes. Saghmos’ lead program, ST …See details»
Saghmos Therapeutics | VentureRadar
Saghmos Therapeutics is a privately held biopharmaceutical company whose mission is to prevent and treat kidney injury due to contrast dyes. Saghmos’ lead program, ST-62516 is …See details»
Saghmos Therapeutics Announces Presentation at the Goldman …
GREENWICH, Conn., May 29, 2024--Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company poised to enter a Phase 3 study of ST-62516 (trimetazidine) to …See details»
Saghmos Therapeutics Announces Presentation at the Goldman …
May 29, 2024 Saghmos Therapeutics, Inc. Anna Kazanchyan, MD Founder and CEO +1 914 522 3885 [email protected] or LaVoie Health Science Katie Dodge Senior Vice President …See details»
Saghmos Therapeutics Announces Presentation at the UBS Global ...
Nov 11, 2024 Saghmos Therapeutics, Inc. Anna Kazanchyan, MD Founder and CEO +1 914 522 3885 [email protected] or LaVoie Health Science Paul Sagan VP, Investor Relations …See details»
Saghmos Therapeutics Announces Notice of Allowance for Second …
Feb 7, 2024 Saghmos Therapeutics is developing ST-62516 (trimetazidine) to reduce the risk of cardiorenal complications after PCI. The company has an issued US patent (Patent number …See details»
Saghmos Therapeutics Announces Issuance of U.S. Patent for …
GREENWICH, Conn., June 05, 2024--Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced that the U.S. Patent and Trademark Office (USPTO) …See details»
Saghmos Therapeutics Welcomes New CRO - Slice of Healthcare
Feb 26, 2024 Stephen Grant, MD, joins Saghmos Therapeutics as Chief Regulatory Officer, bringing over 20 years of FDA experience. Saghmos is developing ST-62516 (trimetazidine), …See details»
New study results reinforce Tagrisso as the backbone therapy for …
1 day ago New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy …See details»